

ASX Release

Dr John Maher Appointed to SUDA's iNKT Cell Therapy Scientific Advisory Board

PERTH, AUSTRALIA – 3 September 2021: SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, has appointed Dr John Maher to its Scientific Advisory Board for the iNKT cell therapy platform.

Dr Maher is an internationally recognised clinical immunologist, focused on the development of chimeric antigen receptor (CAR) cell therapies. Dr Maher played a key role in the early development of second-generation CAR technology while a visiting fellow at Memorial Sloan Kettering Cancer Center in the US, an approach that has achieved clinical impact in haematological malignancies and forms the basis for the five FDA approved CAR-T cell therapies. In 2004, Dr Maher established CAR T cell research at King's College London, where he leads the "CAR Mechanics" group, which is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T cells. Dr Maher is also a clinically active consultant immunologist within King's Health Partners and Eastbourne Hospital.

Dr Maher is the scientific founder and Chief Scientific Officer of Leucid Bio, a clinical stage cell therapy company with a pipeline of novel CAR T cell therapies developed using its proprietary engine.

SUDA's CEO and MD, Dr Michael Baker, commented "Dr Maher has a tremendous amount of experience in developing cell therapies and unique CARs across the preclinical and clinical settings. We are delighted with his appointment to our Scientific Advisory Board and we look forward to his contributions for the development of our iNKT cell therapy platform."

For and on behalf of the Board and for further information, please contact:

Dr Michael Baker
Chief Executive Officer & Managing Director
SUDA Pharmaceuticals Ltd
Tel +61 (0) 403 468 187
mbaker@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a biotechnology company focused on developing therapies to treat human disease. SUDA's two focus areas are oncology and conditions that impact the central nervous system. SUDA is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers. The Company is also developing low-risk oral sprays to reformulate existing pharmaceuticals. The potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes an oral spray for the platelet-lowering drug anagrelide to treat metastatic disease in the background of high platelets, and ZolpiMist™, a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. ZolpiMist is approved by the FDA and the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

For more information, visit www.sudapharma.com

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding actions of third parties and financial terms. These factors and assumptions are based upon currently available information and the forward-looking statements contained herein speak only as of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include, but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.